source
- Novo and Pfizer appoint new CFOs while Alnylam sees departure of its chief commercial officerNovo announced the appointment of a new chief financial officer as part of its effort to improve financial leadership. The hire follows earlier reports that the company is seeking to turn a corner…
- FDA grants accelerated approval for Rybrevant Faspro in recurrent/metastatic head and neck cancerThe U.S. Food and Drug Administration granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carci…